NAFLD

Inventiva reports its 2022 full-year results

Retrieved on: 
Wednesday, March 29, 2023
Income tax, Partnership, BofA Securities, NASH, Tax, Type 2 diabetes, G&A, IP, USD, Sale, Sino Biopharmaceutical Limited, Euronext Paris, Patent, Patient, AbbVie, Fatty liver disease, NAFLD, R, EIB, European Investment Bank, FDA, LTD, Phase, T2D, Cryptocurrency, Pharmaceutical industry, Credit, Medical device

Frédéric Cren, Chairman, CEO and cofounder of Inventiva, stated: “2022 has been a successful year for Inventiva in many ways.

Key Points: 
  • Frédéric Cren, Chairman, CEO and cofounder of Inventiva, stated: “2022 has been a successful year for Inventiva in many ways.
  • Net cash used in operating activities amounted to (€44.9) million for the full year 2022, compared to (€47.6) million in 2021.
  • Net cash generated from financing activities amounted to €37.3 million for the full year 2022 compared to €25.4 million for 2021.
  • Income tax amounted to €0 million for the 2022 fiscal year, compared to (€0.4) million for 2021.

Better Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, March 30, 2023
Cardiology, Software, Telemedicine, Virtual Medicine, Internet, Health, Diabetes, Data Management, Technology, Proton, Real-World Evidence, Workforce, Liver disease, Data set, Fatty liver disease, Cognitive behavioral therapy, Non-alcoholic fatty liver disease, Additive effect, American Diabetes Association, Magnetic resonance, Regulation Fair Disclosure, NASH, Classification, American College of Cardiology, American Heart Association, Marketing, Diabetes Care, Disclosure, Food and Drug Administration, Clinical trial, Type 2 diabetes, PDT, Biomarker, Better, CBT, Trial of the century, Regulation, Patient, Webcast, NAFLD, Research, American College, FDA, Magnetic resonance imaging, Therapy, T2D, Food, Pharmaceutical industry, Cryptocurrency

Publication of BT-001 Pivotal Clinical Trial Results: In October 2022, results from Better Therapeutics’ pivotal clinical trial of BT-001 in adult patients with T2D were published in the American Diabetes Association-produced, peer-reviewed journal Diabetes Care.

Key Points: 
  • Publication of BT-001 Pivotal Clinical Trial Results: In October 2022, results from Better Therapeutics’ pivotal clinical trial of BT-001 in adult patients with T2D were published in the American Diabetes Association-produced, peer-reviewed journal Diabetes Care.
  • Company Announces Restructuring To Preserve Cash Runway: In March 2023, Better Therapeutics announced it would implement a reduction in force impacting 35% of the workforce.
  • Better Therapeutics periodically provides other information for investors on its corporate website, http://www.bettertx.com , and its investor relations website, https://investors.bettertx.com .
  • Accordingly, investors should monitor Better Therapeutics’ website, in addition to following its press releases, SEC filings, and public conference calls and webcasts.

Validation of a Pragmatic Clinical Risk-Based Classification of NASH - New Supporting Real World Evidence from TARGET-NASH

Retrieved on: 
Thursday, March 30, 2023
Interim, Non-alcoholic fatty liver disease, Nutrition, Carcinoma, Classification, Liver disease, LACE, Research, MACE, Elastography, Fibrosis, Journal of Clinical Gastroenterology, LSM, HIV disease progression rates, Journal of Clinical Pathology, Patient, Risk, Division, Fatty liver disease, Liver, NAFLD, Mortality, FDA, VCU School of Medicine, Death, Clinical, HCC, Safety, Dietary supplement, Medical imaging, Medicine, Hepatology, Gastroenterology, Physiology

"Validation of a Clinical Risk-Based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort," was published in the peer-reviewed publication Clinical Gastroenterology and Hepatology .

Key Points: 
  • "Validation of a Clinical Risk-Based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort," was published in the peer-reviewed publication Clinical Gastroenterology and Hepatology .
  • More than 20% of the US population is affected by NAFLD, which represents a major and growing public health concern with significant health economic implications.
  • While there are no approved curative therapies to date, there are multiple new therapies currently under review with the FDA.
  • Identifying patient populations in the real world who will need these upcoming treatments will be critical when these novel treatments become available.

Cardiometabolic Health Congress to Present at the National Lipid Association 2023 Scientific Sessions

Retrieved on: 
Thursday, March 23, 2023
Omni, CNN Center, CME, Obesity, Cardiovascular disease, Myocardial infarction, MI, NASH, Lipid, Diabetes, Chronic kidney disease, Clinical trial, National Lipid Association, Medicine, CHCP, Doctor of Philosophy, Trial of the century, Translation, CMHC, Student, Patient, Fatty liver disease, RWE, Knowledge, NAFLD, CKD, NLA, Education, Organization, Dietary supplement, Nursing

The NLA 2023 Scientific Sessions center on optimizing lipid management in complex patients, the clinical trial landscape, statin intolerance, lipid-lowering drug interactions, and other topics relevant to lipid specialists.

Key Points: 
  • The NLA 2023 Scientific Sessions center on optimizing lipid management in complex patients, the clinical trial landscape, statin intolerance, lipid-lowering drug interactions, and other topics relevant to lipid specialists.
  • This year, CMHC has been selected to present at the NLA 2023 Scientific Sessions on educational outcomes from a CME activity highlighting the improvement in clinician knowledge and competence about treatment choices for lowering LDL-C after myocardial infarction (MI).
  • Co-author and CMHC senior clinical manager Neha Agarwal, PhD, will present the original abstract live from the Omni Atlanta Hotel at CNN Center on June 1-4, 2023.
  • Lipid management is just one facet of the complex field of cardiorenal metabolic health, a fast-growing and increasingly relevant field of medicine and clinical study.

Tempo Bioscience Expands Human Liver Models for Toxicity Evaluation and Disease Modeling

Retrieved on: 
Wednesday, March 15, 2023
Health, Stem Cells, Health Technology, Research, Science, Pharmaceutical, Biotechnology, Cirrhosis, Drug discovery, Drug development, HCC, Non-alcoholic fatty liver disease, Hepatocellular carcinoma, NASH, Toxicity, Organoid, Safety, 3D, NAFLD, Model, Vaccine

Together, Tempo-iHepStellate™-iKupffer™-iLSEC™-iHep3D™ form human liver organoids for modeling diseases such as Nonalcoholic Steatohepatitis (NASH), Nonalcoholic fatty liver disease (NAFLD), liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC).

Key Points: 
  • Together, Tempo-iHepStellate™-iKupffer™-iLSEC™-iHep3D™ form human liver organoids for modeling diseases such as Nonalcoholic Steatohepatitis (NASH), Nonalcoholic fatty liver disease (NAFLD), liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC).
  • Derivative cell types from human iPSCs offer purity of genetic materials, human relevance, and robust patient matched models.
  • Tempo Bioscience is the sole manufacturer of human iPSC-derived cell types that are engineered using non-viral, nucleic-acids-free, serum-free, and feeder-free technologies.
  • Tempo is committed to advancing technologies that focus on disease modeling and drug safety evaluations using advanced human iPSC-derived cell models in 2D, as well as in 3D as spheroids or organoids.

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 14, 2023
Research, Surgery, Health Technology, Other Health, Radiology, Health, General Health, Other Science, Science, Silicon, PIN, International, Silicon Valley Bank, De novo, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Risk, MRI, Federal Deposit Insurance Corporation, Patient, NDRA, GE HealthCare, Liver disease, Temperature, FDA, GE, Food, NAFLD, Non-alcoholic fatty liver disease, Cryptocurrency, Medical imaging, Video game

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months and year ended December 31, 2022, and provided a business update.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months and year ended December 31, 2022, and provided a business update.
  • Highlights include:
    Over 100 TAEUS system scans performed at global clinical evaluation sites in 2022 and deployed a new interactive guidance tool.
  • In 2022, the ENDRA team met with prospective customers and key partners at 11 clinical conferences in the U.S. and Europe.
  • In 2022, 19 patents were issued to ENDRA, including two U.S. patents announced in the fourth quarter.

American Liver Foundation Applauds Expansion of Hepatitis C Screening in President's Budget Proposal

Retrieved on: 
Friday, March 10, 2023
Administration, Hepatitis C, Liver disease, Fatty liver disease, Diagnosis, NAFLD, Pharmaceutical industry, Dietary supplement

FAIRFIELD, N.J., March 10, 2023 /PRNewswire/ -- "We applaud President Biden's budget proposal to expand hepatitis C screening, testing, treatment, prevention, and monitoring. The proposed subscription model for drugs to treat hepatitis C and related infrastructure support would be an important step forward towards increasing access to these liver-saving treatments. We thank the President and his administration for their leadership in addressing this critical issue."

Key Points: 
  • FAIRFIELD, N.J., March 10, 2023 /PRNewswire/ -- "We applaud President Biden's budget proposal to expand hepatitis C screening, testing, treatment, prevention, and monitoring.
  • The proposed subscription model for drugs to treat hepatitis C and related infrastructure support would be an important step forward towards increasing access to these liver-saving treatments.
  • "We also ask that the Administration take similar action for nonalcoholic fatty liver disease (NAFLD), a form of liver disease affecting 80-100 million Americans , most of whom are unaware they even have it.
  • NAFLD is a growing epidemic and can be life-threatening without early screening and accurate diagnosis."

MRM Health Completes Patient Recruitment in Ulcerative Colitis Study, Secures Financing and Provides Outlook for 2023

Retrieved on: 
Tuesday, March 7, 2023
University, Biotechnology, Education, Other Health, Health, General Health, Pharmaceutical, Other Science, Research, Science, Clinical Trials, DSM-IV codes, Cirrhosis, VIB, Non-alcoholic fatty liver disease, Therapy, CGMP, Type 2 diabetes, Partnership, Regression dilution, Patient, Disease, Neuroinflammation, United States patent law, Patent, Safety, MRM, UC, Fine chemical, Pharmaceutical industry, NAFLD, T2D, Spondyloarthropathy, PD, Ulcerative colitis

“2023 also started very promising as we reached a major milestone by completing early January patient recruitment in the Phase 2a study with MH002 in Ulcerative Colitis, while patient recruitment in our phase 2 study in Acute Pouchitis continues to progress.

Key Points: 
  • “2023 also started very promising as we reached a major milestone by completing early January patient recruitment in the Phase 2a study with MH002 in Ulcerative Colitis, while patient recruitment in our phase 2 study in Acute Pouchitis continues to progress.
  • MRM Health has now enrolled all 45 mild-to-moderate UC patients.
  • MRM Health has an ongoing corporate partnership with IFF since 2020, aiming to tackle a range of metabolic diseases.
  • As part of its ongoing program in T2D, MRM Health recently reached a next milestone upon successfully achieving preclinical development targets.

Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates

Retrieved on: 
Wednesday, March 1, 2023
ENDO, Non-alcoholic fatty liver disease, Massachusetts General Hospital, Rare, Argentina, Interim, Depreciation, Travel, Endocrinology, Patent, LUMO, Clinical trial, DRS, Abstract, Therapy, Internet, Research, Czech Institute For International Meetings, Growth, Investment, Pediatric endocrinology, Pharmaceutical industry, Cryptocurrency, NAFLD, Idiopathic disease

AUSTIN, Texas, March 01, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced financial results for the year ended December 31, 2022.

Key Points: 
  • AUSTIN, Texas, March 01, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced financial results for the year ended December 31, 2022.
  • Data from the interim analysis of our OraGrowtH210 Trial showed LUM-201 met growth expectations, showed durable response and was well-tolerated.
  • Financial Results for the Year Ended December 31, 2022
    Cash Position – Lumos Pharma ended the year on December 31, 2022, with cash, cash equivalents, and short-term investments totaling $67.4 million compared to $94.8 million on December 31, 2021.
  • Lumos Pharma ended Q4 2022 with 8,267,968 shares outstanding.

Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update

Retrieved on: 
Tuesday, February 28, 2023
Type 2 diabetes, Blood pressure, Diabetes, ET, Human, Weight loss, Fibrosis, Non-alcoholic fatty liver disease, Research, Heart rate, Three Months, Investment, ALT, Patent, Medicine, Diet, Diabetes management, NAFLD, Principal investigator, Exercise, Government, NASH, Vital signs, University of Oxford, United States Patent and Trademark Office, Glycated hemoglobin, CT1, Weill Cornell Medicine, Hepatitis, Obesity, Overweight, Cryptocurrency, Dietary supplement, Medical imaging, Pharmaceutical industry, Webcast

GAITHERSBURG, Md., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

Key Points: 
  • Webcast to be held today, February 28, 2023, at 8:30 am ET
    GAITHERSBURG, Md., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.
  • We expect the key endpoints of this trial to be NASH resolution and fibrosis improvement, both assessed following 24 weeks of treatment.
  • Financial Results for the Three Months Ended December 31, 2022
    Altimmune had cash, cash equivalents and short-term investments totaling $184.9 million at December 31, 2022.
  • General and administrative expenses were consistent period-over-period at $3.8 million for each of the three months ended December 31, 2022 and 2021.